Alti-Mpa Oral

Name: Alti-Mpa Oral

Important information

You should not use medroxyprogesterone if you are pregnant, or if you have liver disease, a hormone-related cancer such as breast or uterine cancer, a history of stroke or blood clot, or abnormal vaginal bleeding that has not been checked by a doctor.

Medroxyprogesterone should not be used to prevent heart disease, stroke, or dementia. This medicine may actually increase your risk of developing these conditions. Long-term use of medroxyprogesterone may increase your risk of breast cancer, heart attack, stroke, or blood clot. Talk with your doctor about your individual risk.

Usual Adult Dose for Endometriosis

104 mg subcutaneously once every 3 months (12 to 14 weeks)
Duration of therapy: No longer than two years

Comments:
-For sexually active women having regular menses, the first injection should only be given within the first 5 days of a normal menstrual period or at 6 weeks postpartum, if the patient is breast feeding.
-If the period between injections is more than 14 weeks, pregnancy should be ruled out prior to administering.
-The impact of long-term use of the subcutaneous injection on bone mineral density (BMD) should be considered.
-If symptoms return after discontinuation of treatment, BMD should be evaluated prior to retreatment.

Use: Management of endometriosis-associated pain

Usual Adult Dose for Renal Cell Carcinoma

Initial dose: 400 to 1000 mg IM once a week
Maintenance dose: Reduce dose to 400 mg IM once a month to maintain improvement

Comments:
-This drug is not recommended as primary therapy.
-Greater sensitivity in the geriatric population cannot be ruled out.
-The frequency of administration may be reduced if improvement or stabilization occurs, usually within a few weeks to months.

Use: Adjunctive therapy and palliative treatment in advanced inoperable cases including those with recurrent or metastatic endometrial or renal carcinoma

Usual Adult Dose for Endometrial Carcinoma

Initial dose: 400 to 1000 mg IM once a week
Maintenance dose: Reduce dose to 400 mg IM once a month to maintain improvement

Comments:
-This drug is not recommended as primary therapy.
-Greater sensitivity in the geriatric population cannot be ruled out.
-The frequency of administration may be reduced if improvement or stabilization occurs, usually within a few weeks to months.

Use: Adjunctive therapy and palliative treatment in advanced inoperable cases including those with recurrent or metastatic endometrial or renal carcinoma

Medroxyprogesterone Breastfeeding Warnings

Use is not recommended. Excreted into human milk: Yes Comments: -The effects in the nursing infant are unknown.

Although this drug is detectable in the maternal milk, its composition, quality, and amount are not adversely affected. Neonates and infants exposed to this drug from breast milk have been studied for developmental and behavioral effects through puberty, and no adverse effects have been noted.

(web3)